 |
|
First-in-class Therapeutics for Unmet Medical Needs |
 |
Tranzyme Pharma’s strategy is to use its unique drug
discovery capabilities to find effective and safe drugs to treat diseases
where there is a significant unmet medical need. Our business objectives are
to continue to expand and solidify our drug discovery and development expertise
in order to advance our high value drug candidates through the clinical development
process and to make breakthrough mechanism-based therapeutics available to patients.
Tranzyme has launched two Phase IIb clinical trials to test the safety and efficacy of TZP-101, a
ghrelin receptor agonist being investigated for the treatment of severe gastroparesis and post-operative
ileus. TZP-101 has potent prokinetic properties that represent the first in its class to enter
clinical trials. The FDA recently granted fast-track designation to TZP-101 for severe gastroparesis.
Tranzyme is also developing therapeutics to treat chronic gastroparesis, moderate-to-severe diarrhea,
functional gastrointestinal disorders and obesity.
| Pipeline Focused on Key Validated Targets |
|
Tranzyme Pharma is developing novel small molecule drugs targeting
key validated receptors that regulate gastrointestinal motility, appetite and metabolism.
These receptors include ghrelin (responsible for upper gut motility, appetite stimulation,
and energy balance) and motilin (responsible for regulation of gastrointestinal transit).
The ghrelin receptor is considered a drug target of high interest in the pharmaceutical industry. Tranzyme’s
ghrelin agonists, TZP-101 and TZP-102, have been uniquely optimized for their GI activity and are potential
breakthrough blockbuster drugs. Ghrelin agonists are considered one of the most exciting new drug prospects
by gastroenterologists and leading clinical experts have expressed a high degree of interest in them.
Likewise, the motilin receptor has been identified as a key pharmaceutical target for GI disorders due to its
critical regulatory role in the GI physiological system where it governs fasting motor activity. This receptor
controls gastric motility by inducing the contraction of gastrointestinal smooth muscle thereby decreasing
intestinal transit time and initiating phase III of the migrating motor complex (MMC) in the small bowel.
However, to date, the development of small molecule therapeutic agents designed to effectively modulate this
receptor has proven elusive. Motilin antagonists in particular would be quite useful in treating GI diseases
characterized by hypermotility. Tranzyme’s motilin antagonist, TZP-201, has demonstrated efficacy in
multiple animal models of disease, including chemotherapy-induced diarrhea and functional GI disorders.
Details
»
|
Products Based on Proprietary Macrocyclic Drugs |
|
Tranzyme’s pipeline of products originates from its proprietary
Macrocyclic Template Chemistry (MATCH™). MATCH is a drug design and medicinal
chemistry platform which exploits macrocycles, a distinct compound class. Tranzyme
has created the first library of synthetic, low molecular weight macrocyclic molecules
which has proven highly effective in drug target screening programs to supply novel
chemical diversity along with necessary conformational control. We have demonstrated
the ability to develop orally bioavailable small molecules from this chemistry, with
particular success on GPCR targets. Our chemistry and R&D expertise can produce
clinical candidates in a shorter time and more efficiently than current standard drug
discovery approaches. This chemistry also has potential broad applicability in the
treatment of other diseases that involve hormones, peptides or protein-protein
interaction pathways.
Details
»
| Product Focused Business
Strategy |
|
Tranzyme’s objective is to build a pipeline of clinical
stage drugs with multiple therapeutic opportunities. The Company has worked
closely with academic clinical researchers and industry experts to design
product development programs that address the typical hurdles of drug development
in the GI therapeutic area. Tranzyme will develop these products to an optimal
stage and then seek partnerships for further development and commercialization.
Details
»
|
|
|
